Cardiac allograft vasculopathy prevention

Jump to navigation Jump to search

Template:Cardiac Allograft Vasculopathy Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Prevention

As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.

Optimization of Immunosuppressive Therapy

Options for immunosuppressive therapy for prevention of CAV includes:

References

Template:WH Template:WS